Growth Hormone Deficiency Calculator- Free GHD Assessment and GH Stimulation Test Interpreter Tool

About This Growth Hormone Deficiency Calculator

This growth hormone deficiency calculator is designed for healthcare professionals, medical students, patients, and caregivers seeking to understand how key diagnostic parameters contribute to the assessment of GHD probability. The tool evaluates peak growth hormone levels from stimulation tests, IGF-1 standard deviation scores, the number of concurrent pituitary hormone deficiencies, structural MRI findings, and patient demographics to generate a comprehensive GHD probability estimate.

The calculator interprets GH stimulation test results using BMI-adjusted diagnostic cutoffs established by the Endocrine Society, the American Association of Clinical Endocrinologists (AACE), and the Growth Hormone Research Society. It supports five major stimulation test types: the insulin tolerance test (ITT), glucagon stimulation test, GHRH-arginine test, macimorelin oral test, and clonidine stimulation test, each with their specific diagnostic thresholds and clinical considerations.

The reference range bar visualization displays where peak GH and IGF-1 SDS values fall relative to established diagnostic zones, while the clinical decision tree algorithm guides users through the stepwise diagnostic approach recommended by international endocrine guidelines. The tool dynamically adjusts cutoff values based on patient BMI and selected test type, providing clinically relevant interpretation for each individual assessment scenario.

Growth Hormone Deficiency Calculator: Complete Guide to GHD Assessment, Diagnosis, and Stimulation Test Interpretation

Growth hormone deficiency (GHD) is a clinical syndrome characterized by insufficient secretion of growth hormone (GH) from the anterior pituitary gland, affecting approximately 1 in 4,000 to 1 in 10,000 children and 2 to 3 per 10,000 adults worldwide. Whether presenting as childhood-onset GHD causing short stature and delayed growth, or adult-onset GHD resulting in metabolic changes and reduced quality of life, accurate diagnosis requires a systematic evaluation combining clinical assessment, biochemical testing, and imaging studies. This comprehensive calculator helps healthcare professionals and patients understand how key diagnostic parameters interact in the evaluation of suspected growth hormone deficiency.

Understanding Growth Hormone and Its Physiological Role

Growth hormone is a 191-amino acid polypeptide secreted by somatotroph cells in the anterior pituitary gland. Its secretion follows a pulsatile pattern, primarily regulated by two hypothalamic hormones: growth hormone-releasing hormone (GHRH), which stimulates secretion, and somatostatin, which inhibits it. The largest and most predictable GH pulse occurs approximately one hour after the onset of deep sleep, though secretion is also stimulated by exercise, fasting, stress, and certain amino acids.

GH exerts its biological effects both directly and indirectly through insulin-like growth factor 1 (IGF-1), which is primarily produced by the liver. IGF-1 mediates most of the growth-promoting effects of GH and provides a negative feedback signal to the hypothalamus and pituitary. Because GH secretion is pulsatile and highly variable, random GH measurements are unreliable for diagnostic purposes. Instead, clinicians rely on IGF-1 levels, which remain relatively stable throughout the day, and provocative stimulation tests that challenge the pituitary to secrete GH in response to pharmacological agents.

Causes and Classification of Growth Hormone Deficiency

GHD can be classified by onset (childhood versus adult), etiology (congenital versus acquired), and severity (isolated versus combined with other pituitary hormone deficiencies). Childhood-onset GHD is most commonly idiopathic and hypothalamic in origin. Congenital causes include genetic mutations affecting the GH1 gene, GHRH receptor abnormalities, and central nervous system malformations such as septo-optic dysplasia and pituitary stalk interruption syndrome. Acquired causes in children include cranial irradiation, brain tumors (particularly craniopharyngiomas), meningitis, histiocytosis, and traumatic brain injury.

Adult-onset GHD is most commonly caused by hypothalamic-pituitary tumors and their treatment through surgery or radiation therapy. Pituitary adenomas are the most frequent cause, followed by craniopharyngiomas, which together account for approximately 57% of cases. Less common causes include traumatic brain injury, subarachnoid hemorrhage, vascular events, infiltrative diseases, infections, and autoimmune conditions. Importantly, GH is typically the first anterior pituitary hormone to be affected by pathological insults. Consequently, patients with multiple pituitary hormone deficiencies have a very high probability of concurrent GHD.

Clinical Features of Growth Hormone Deficiency

In children, the hallmark features of GHD include diminished height velocity and short stature, typically manifesting as height below the 3rd percentile or more than 2 standard deviations below the mean for age and sex. Growth deceleration, with a height velocity below the 25th percentile, is often the earliest clinical indicator. Other features may include delayed bone age relative to chronological age, increased truncal adiposity, mid-facial hypoplasia (in severe or congenital cases), micropenis in male neonates, and neonatal hypoglycemia. Children with combined pituitary hormone deficiencies may also present with signs of thyroid hormone, cortisol, or gonadotropin deficiency.

In adults, the clinical syndrome of GHD is more subtle and nonspecific. Features include decreased lean body mass, increased central adiposity, reduced exercise capacity, decreased bone mineral density, dyslipidemia with elevated LDL cholesterol, decreased quality of life characterized by fatigue and reduced psychological well-being, and an increased predisposition to cardiovascular disease. Because these symptoms are nonspecific, diagnostic workup for adult GHD should generally only be undertaken when there is reasonable clinical suspicion, such as a history of childhood GHD, structural hypothalamic-pituitary disease, or evidence of other pituitary hormone deficiencies.

Diagnostic Approach: When to Test for GHD

The decision to pursue evaluation for GHD should be guided by clinical context and probability of disease. In children, the GH Research Society consensus guidelines recommend evaluation when specific auxological criteria are met, including severe short stature (height below -3 SDS), height more than 1.5 SDS below the mid-parental height, height below -2 SDS combined with a growth velocity below the 25th percentile, or a decrease in height SDS of more than 0.5 over one year. Evaluation is also indicated in children with known risk factors such as prior cranial irradiation, other pituitary hormone deficiencies, or suggestive radiological findings.

In adults, the Endocrine Society recommends evaluation for patients with structural hypothalamic-pituitary disease, those who have undergone surgery or irradiation in the hypothalamic-pituitary region, patients with traumatic brain injury, and those with evidence of other pituitary hormone deficiencies. Idiopathic adult-onset GHD is extremely rare, and stringent criteria are necessary for this diagnosis, typically requiring two failed stimulation tests along with a low IGF-1 level. Patients with childhood-onset GHD should be retested after achieving adult height, unless they have known genetic mutations, embryopathic lesions, or irreversible structural damage causing multiple hormone deficiencies.

Growth Hormone Stimulation Tests: Types and Interpretation

Because random GH levels are unreliable due to the pulsatile nature of GH secretion, provocative stimulation tests are the cornerstone of biochemical diagnosis. These tests involve administering a pharmacological agent that stimulates pituitary GH release, followed by serial blood sampling to measure the peak GH response. The choice of stimulation test depends on the clinical context, patient characteristics, contraindications, and local availability.

The insulin tolerance test (ITT) has long been considered the reference standard for diagnosing GHD in both children and adults. It involves intravenous administration of regular insulin (0.1 U/kg) to induce hypoglycemia (blood glucose below 40 mg/dL or 2.2 mmol/L), which is a potent stimulus for GH release. A peak GH response below 3 ng/mL in adults (or below 5 ng/mL by some criteria) confirms severe GHD. However, the ITT is contraindicated in elderly patients, those with a history of seizures, cardiovascular disease, or cerebrovascular disease, and requires close medical supervision with continuous monitoring.

The glucagon stimulation test (GST) has become the most commonly used alternative, owing to its safety profile, reproducibility, and lack of influence by hypothalamic etiology. Intramuscular glucagon is administered at a dose of 1 mg (1.5 mg for patients weighing more than 90 kg), with GH levels measured at baseline and every 30 minutes for 4 hours. Diagnostic cutoffs are BMI-dependent: a peak GH below 3 ng/mL for patients with BMI below 30 kg/m2, and below 1 ng/mL for patients with BMI of 30 kg/m2 or greater.

The Role of IGF-1 in GHD Diagnosis

Serum IGF-1 is the principal biochemical surrogate marker of GH secretion. Unlike GH, IGF-1 levels remain relatively stable throughout the day without significant pulsatile variation, making a single measurement clinically useful. IGF-1 levels should be interpreted relative to age- and sex-specific reference ranges, typically expressed as standard deviation scores (SDS). An IGF-1 SDS below -2 is considered low and suggestive of GHD, while an IGF-1 SDS below 0 in the appropriate clinical context may also raise suspicion.

However, IGF-1 levels have important limitations in GHD diagnosis. A normal IGF-1 does not exclude GHD, as overlap exists between GH-deficient and GH-sufficient populations, particularly in children with idiopathic GHD. Conversely, low IGF-1 levels can occur in conditions other than GHD, including malnutrition, chronic liver disease, poorly controlled diabetes, hypothyroidism, and the use of oral estrogens. For these reasons, IGF-1 measurement should not be used in isolation for diagnosis but rather integrated with clinical assessment, auxological data, and stimulation test results.

IGF binding protein 3 (IGFBP-3) is the major carrier protein for IGF-1 in the circulation and is also GH-dependent. While IGFBP-3 can provide supplementary diagnostic information, it has similar limitations to IGF-1 and is less widely used in current clinical practice. The combination of IGF-1 and IGFBP-3 measurements may improve diagnostic accuracy compared with either test alone, particularly in younger children where IGF-1 levels are physiologically low.

Macimorelin: The Oral Diagnostic Test

Macimorelin is an orally administered ghrelin agonist approved by regulatory agencies for the diagnosis of adult GHD. It stimulates GH secretion through the ghrelin receptor (GHS-R1a) pathway, which is distinct from the GHRH pathway. The test is straightforward: after an overnight fast, patients ingest a single dose of macimorelin (0.5 mg/kg dissolved in water), and GH levels are measured at baseline, 30, 45, 60, and 90 minutes.

A peak GH level below 2.8 ng/mL confirms GHD with good sensitivity and specificity. Macimorelin offers several advantages over traditional stimulation tests, including oral administration, a shorter testing duration, fewer adverse effects, and no risk of hypoglycemia. However, it should not be used in patients taking strong CYP3A4 inhibitors, and its diagnostic performance may be affected by recent GH therapy. Availability and cost considerations may also limit its use in some clinical settings.

Pediatric Considerations in GHD Diagnosis

The diagnosis of GHD in children requires special consideration due to the age-dependent nature of GH secretion and the influence of pubertal status on test results. The currently agreed-upon peak GH cutoff for pediatric stimulation tests is 10 ng/mL, though proposed values of 5, 7, and 10 ng/mL exist on a continuum without definitive evidence supporting any single threshold. Two separate stimulation tests failing to produce an adequate GH response are typically required for diagnosis, except in specific circumstances where the pretest probability is very high.

Sex steroid priming before stimulation testing remains controversial. Some experts advocate for estrogen or testosterone priming in prepubertal children to reduce false-positive results, particularly in those with constitutional delay of growth and puberty. Without priming, prepubertal children may have falsely low GH responses, leading to overdiagnosis of GHD. However, standardized protocols for sex steroid priming are not universally established.

For neonates, stimulation testing is not required if all three of the following criteria are met: documented hypoglycemia, a serum GH level of 5 ng/mL or less, and either a deficiency in another pituitary hormone or ectopic posterior pituitary with pituitary hypoplasia and an abnormal stalk. In older children with established genetic causes, irreversible structural lesions, or panhypopituitarism with low IGF-1, repeated stimulation testing is generally unnecessary.

Transition Period: Retesting from Childhood to Adulthood

Patients diagnosed with childhood-onset GHD face a critical transition period when they reach adult height. Because a significant proportion of children with idiopathic isolated GHD will have normal GH secretion when retested as adults, retesting is recommended after completion of linear growth. Testing should be performed at least one month after discontinuing GH therapy to allow recovery of the hypothalamic-pituitary-GH axis.

Retesting is generally not required for patients with documented genetic or congenital causes of GHD, irreversible hypothalamic-pituitary structural abnormalities, or multiple pituitary hormone deficiencies with low IGF-1 levels. For those requiring retesting, adult diagnostic criteria and cutoff values should be applied, as pediatric cutoffs of 10 ng/mL would be overly stringent for adult assessment. The ITT and macimorelin are the preferred tests for transition patients.

Body Mass Index and Its Impact on GH Testing

Obesity and elevated BMI significantly affect GH secretion and stimulation test results. Elevated free fatty acid levels in individuals with obesity cause a reversible suppression of GH secretion, leading to lower peak GH values on stimulation testing. This effect can produce false-positive diagnoses of GHD in obese individuals. For this reason, BMI-adjusted cutoff values are used for certain tests, particularly the GHRH-arginine test and the glucagon stimulation test.

With the glucagon stimulation test, the recommended cutoffs are peak GH below 3 ng/mL for patients with BMI below 25 or BMI 25 to 30 with high pretest probability, and peak GH below 1 ng/mL for patients with BMI of 30 or greater or BMI 25 to 30 with low pretest probability. Similarly, the GHRH-arginine test uses cutoffs of 11 ng/mL for BMI below 25, 8 ng/mL for BMI 25 to 30, and 4.2 ng/mL for BMI above 30. BMI-adjusted reference intervals have not been established for pediatric patients.

Imaging in GHD Assessment

Magnetic resonance imaging (MRI) of the hypothalamic-pituitary region plays an important role in the diagnostic evaluation of GHD. In children, MRI may reveal congenital abnormalities such as anterior pituitary hypoplasia, ectopic posterior pituitary bright spot, pituitary stalk interruption syndrome, or developmental cysts. It may also identify acquired lesions such as tumors, particularly craniopharyngiomas. The presence of structural pituitary abnormalities suggests a higher likelihood of persistent GHD requiring ongoing treatment.

In adults, MRI is essential to identify the underlying etiology, such as pituitary adenomas, craniopharyngiomas, or evidence of prior surgery or radiation. The imaging findings help guide decisions about the need for stimulation testing, the type of test to use, and the expected likelihood of GHD. Patients with normal pituitary MRI and idiopathic GHD require more stringent diagnostic criteria than those with obvious structural abnormalities.

GH Replacement Therapy Considerations

Once GHD is confirmed, recombinant human GH (rhGH) therapy is the standard treatment for both children and adults. In children, the primary goal is to promote linear growth and achieve a normal adult height. Dosing is typically weight-based, starting at 0.16 to 0.24 mg/kg per week divided into daily subcutaneous injections. The dose is adjusted based on growth response, IGF-1 levels, and side effects.

In adults, GH replacement addresses the metabolic and quality-of-life consequences of GHD. Treatment typically begins at a low dose (0.1 to 0.2 mg daily for younger adults, 0.1 mg daily for older adults) and is titrated based on clinical response, IGF-1 levels maintained within the age-adjusted reference range, and side effects. Common adverse effects include fluid retention, arthralgia, myalgia, and paresthesias, which are usually dose-related and resolve with dose reduction. Long-acting GH preparations that allow weekly or less frequent dosing are becoming available, potentially improving adherence and convenience.

Alternative and Regional Diagnostic Approaches

While this calculator follows internationally recognized diagnostic criteria, it is worth noting that some regions and institutions use alternative or supplementary assessment tools. The clonidine stimulation test is commonly used as a first-line test in many pediatric centers, though it has lower sensitivity compared with arginine or insulin-based tests. The levodopa (L-DOPA) stimulation test is another option, though it similarly has limitations in specificity.

Spontaneous nocturnal GH secretion profiling, where blood samples are collected every 20 to 30 minutes overnight, can provide complementary information to stimulation testing. Studies suggest that combining nocturnal profiling with a single stimulation test may reduce the risk of overdiagnosing GHD compared with relying on stimulation testing alone. However, this approach is labor-intensive, costly, and not widely available in routine clinical practice.

Limitations and Caveats in GH Testing

Several important factors can confound the interpretation of GH stimulation test results. Assay heterogeneity remains a significant challenge, as different immunoassays can yield substantially different GH values for the same sample due to variations in antibody specificity, calibration standards, and cross-reactivity with GH isoforms and binding proteins. This means that cutoff values established with one assay may not be directly applicable to another.

Other confounding factors include patient age (GH secretion declines with aging), sex (estrogen enhances GH secretion), pubertal status (GH secretion increases two- to three-fold during mid-puberty), nutritional status (malnutrition suppresses IGF-1 production), concurrent medications (glucocorticoids suppress GH secretion; estrogens lower IGF-1 through hepatic effects), and body composition (obesity suppresses GH responses). Additionally, patients should be adequately replaced with other deficient hormones before GH testing, as untreated hypothyroidism or cortisol deficiency can affect test results.

Global Application and Population Considerations

Growth hormone deficiency has been studied across diverse populations worldwide, and diagnostic approaches are broadly similar across international guidelines from the Endocrine Society, the American Association of Clinical Endocrinologists (AACE), the GH Research Society, and the European Society of Endocrinology. However, some studies suggest that GH stimulation test cutoffs established primarily in Western populations may not be equally applicable across all ethnic groups.

For example, some data indicate that the Framingham-derived reference ranges may not perfectly translate to East Asian or South Asian populations. Healthcare providers should be aware of population-specific considerations when interpreting test results and should use locally validated reference ranges for IGF-1 when available. The assay-specific nature of GH and IGF-1 measurements further reinforces the importance of using the same laboratory and assay method for longitudinal follow-up of individual patients.

Quality of Life Assessment in Adult GHD

The QoL-AGHDA (Quality of Life Assessment of Growth Hormone Deficiency in Adults) questionnaire is a validated tool specifically designed to assess quality of life in adults with GHD. It consists of 25 yes/no questions covering dimensions such as energy, emotional reactions, social isolation, and perceived health. Higher scores indicate worse quality of life. While not part of the biochemical diagnostic workup, the QoL-AGHDA can help guide treatment decisions and monitor therapeutic response.

Other assessments used in clinical practice include measures of body composition (waist circumference, body fat percentage), bone mineral density (DEXA scan), lipid profiles, fasting glucose and insulin levels, and cardiovascular risk assessment. These comprehensive evaluations help establish the clinical impact of GHD and the potential benefits of replacement therapy for individual patients.

Frequently Asked Questions

Conclusion

Growth hormone deficiency assessment requires a thoughtful, systematic approach that integrates clinical history, physical examination, auxological data, biochemical testing, and imaging. No single test or measurement can confirm or exclude GHD in isolation. This calculator serves as an educational tool to help users understand the diagnostic framework and how different parameters contribute to the overall assessment of GHD probability. The appropriate interpretation of stimulation test results requires attention to the specific test used, patient BMI, age, pubertal status, and the clinical context. Healthcare professionals should use their clinical judgment in conjunction with established guidelines when making diagnostic and therapeutic decisions regarding growth hormone deficiency.